<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Arab J Urol</journal-id><journal-id journal-id-type="iso-abbrev">Arab J Urol</journal-id><journal-title-group><journal-title>Arab Journal of Urology</journal-title></journal-title-group><issn pub-type="ppub">2090-598X</issn><issn pub-type="epub">2090-5998</issn><publisher><publisher-name>Elsevier</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">27547466</article-id><article-id pub-id-type="pmc">4983165</article-id><article-id pub-id-type="publisher-id">S2090-598X(16)30033-X</article-id><article-id pub-id-type="doi">10.1016/j.aju.2016.05.003</article-id><article-categories><subj-group subj-group-type="heading"><subject>Original Article</subject></subj-group></article-categories><title-group><article-title>Fosfomycin antimicrobial prophylaxis for transrectal ultrasound-guided biopsy of the prostate: A prospective randomised study</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Fahmy</surname><given-names>Ahmed M.</given-names></name><email>drahmedfahmy@yahoo.com</email><xref rid="cor1" ref-type="corresp">&#x0204e;</xref></contrib><contrib contrib-type="author"><name><surname>Kotb</surname><given-names>Ahmed</given-names></name></contrib><contrib contrib-type="author"><name><surname>Youssif</surname><given-names>Tamer Abo</given-names></name></contrib><contrib contrib-type="author"><name><surname>Abdeldiam</surname><given-names>Hussien</given-names></name></contrib><contrib contrib-type="author"><name><surname>Algebaly</surname><given-names>Omer</given-names></name></contrib><contrib contrib-type="author"><name><surname>Elabbady</surname><given-names>Ahmed</given-names></name></contrib></contrib-group><aff id="af005">Department of Urology, Alexandria University, Alexandria, Egypt</aff><author-notes><corresp id="cor1"><label>&#x0204e;</label>Corresponding author at: Alexandria University, 41 St Abdelmoneam Sanad, Kampsizaar, Alexandria, Egypt.Alexandria University41 St Abdelmoneam SanadKampsizaarAlexandriaEgypt <email>drahmedfahmy@yahoo.com</email></corresp></author-notes><pub-date pub-type="pmc-release"><day>27</day><month>6</month><year>2016</year></pub-date><!-- PMC Release delay is 0 months and 0 days and was based on <pub-date
						pub-type="epub">.--><pub-date pub-type="collection"><month>9</month><year>2016</year></pub-date><pub-date pub-type="epub"><day>27</day><month>6</month><year>2016</year></pub-date><volume>14</volume><issue>3</issue><fpage>228</fpage><lpage>233</lpage><history><date date-type="received"><day>13</day><month>3</month><year>2016</year></date><date date-type="rev-recd"><day>27</day><month>4</month><year>2016</year></date><date date-type="accepted"><day>11</day><month>5</month><year>2016</year></date></history><permissions><copyright-statement>&#x000a9; 2016 Arab Association of Urology. Production and hosting by Elsevier B.V.</copyright-statement><copyright-year>2016</copyright-year><copyright-holder>Arab Association of Urology</copyright-holder><license license-type="CC BY-NC-ND" xlink:href="http://creativecommons.org/licenses/by-nc-nd/4.0/"><license-p>This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).</license-p></license></permissions><abstract id="ab005"><sec><title>Objectives</title><p>To compare the incidence of infectious complications after single-dose fosfomycin vs. standard fluoroquinolone (FQ)-based prophylaxis in patients undergoing transrectal ultrasound-guided biopsy of the prostate (TRUSBx), as there is an alarming trend worldwide of increasing resistance to FQs limiting their suitability as appropriate prophylaxis for TRUSBx.</p></sec><sec><title>Patients and methods</title><p>A prospective study was conducted in 412 consecutive patients undergoing TRUSBx between February 2012 and June 2015. Patients were randomly divided into two groups; Group 1 (202 patients) who received single-dose fosfomycin (3&#x000a0;g, orally) 1&#x02013;2&#x000a0;h before TRUSBx and Group 2 (210 patients) who received routine empirical prophylaxis in the form of oral ciprofloxacin 500&#x000a0;mg and metronidazole 500&#x000a0;mg at least 1&#x000a0;h before TRUSBx and continued this twice daily for 3&#x000a0;days before TRUSBx. We recorded all febrile and afebrile urinary tract infections (UTIs) within the 4&#x000a0;weeks after the procedure.</p></sec><sec><title>Results</title><p>There was no difference in baseline demographics between the two groups. Total infectious complications occurred in four (1.9%) and 18 (8.5%) patients in Groups 1 and 2, respectively, which was statistically significant (<italic>P</italic>&#x000a0;=&#x000a0;0.001). <italic>Escherichia coli</italic> was the most common isolated pathogen from urine cultures in all patients with infectious complications (68%). The other isolated bacterium, <italic>Klebsiella pneumoniae</italic>, was detected in four patients (18%). Urine cultures revealed FQ-resistant strains (73%), all of which were extended-spectrum &#x003b2;-lactamase-producing <italic>E. coli</italic> and <italic>K. pneumoniae</italic>.</p></sec><sec><title>Conclusions</title><p>Single-dose fosfomycin before TRUSBx significantly reduces infectious complications when compared with standard therapy. Fosfomycin is an effective agent for antimicrobial prophylaxis in patients undergoing TRUSBx, particularly in populations where FQ resistance is common.</p></sec></abstract><kwd-group id="kg005"><title>Abbreviations</title><kwd>ESBL, extended-spectrum &#x003b2;-lactamase</kwd><kwd>FQ, fluoroquinolone</kwd><kwd>MDR, multidrug-resistant</kwd><kwd>TRUSBx, TRUS-guided biopsy of the prostate</kwd></kwd-group><kwd-group id="kg010"><title>Keywords</title><kwd>Fosfomycin</kwd><kwd>Antimicrobial prophylaxis</kwd><kwd>Transrectal ultrasound-guided biopsy</kwd><kwd>Prostate</kwd></kwd-group></article-meta><notes><p id="ms005">Prostatic Disorders</p></notes></front><body><sec id="s0005"><title>Introduction</title><p>The risk of infection-related complications after TRUS-guided prostate biopsy (TRUSBx) has increased. Clinically significant infectious complications include UTI, acute bacterial prostatitis, epididymo-orchitis, and even life-threatening sepsis <xref rid="b0005" ref-type="bibr">[1]</xref>. There is no currently accepted optimal prophylactic antibiotic regimen before TRUSBx. The value of antibiotic prophylaxis in reducing the incidence of such complications have been documented in several studies; however, there are wide variations in antibiotic regimens and administration among different centres, with none clearly better than another <xref rid="b0010" ref-type="bibr">[2]</xref>, <xref rid="b0015" ref-type="bibr">[3]</xref>.</p><p>Fluoroquinolone (FQ) antibiotics, which reach high concentrations in the prostate after oral administration, are routinely used to reduce the risk of infectious complication after TRUSBx because of broad spectrum activity against Gram-positive and Gram-negative organisms <xref rid="b0010" ref-type="bibr">[2]</xref>, <xref rid="b0020" ref-type="bibr">[4]</xref>, <xref rid="b0025" ref-type="bibr">[5]</xref>. Unfortunately, many recent studies have identified an alarming trend of increasing resistance to FQs worldwide, limiting their suitability as appropriate prophylaxis <xref rid="b0030" ref-type="bibr">[6]</xref>, <xref rid="b0035" ref-type="bibr">[7]</xref>, <xref rid="b0040" ref-type="bibr">[8]</xref>. In the wake of the increased FQ resistance in <italic>Escherichia coli</italic> strains, several interventional studies have compared different antibiotic prophylactic regimens before TRUSBx <xref rid="b0045" ref-type="bibr">[9]</xref>, <xref rid="b0050" ref-type="bibr">[10]</xref>, <xref rid="b0055" ref-type="bibr">[11]</xref>, <xref rid="b0060" ref-type="bibr">[12]</xref>.</p><p>Fosfomycin is an oral, bactericidal, broad-spectrum antibiotic with favourable pharmacokinetic and pharmacodynamics profile that promotes its effectiveness against UTIs. Specifically, after a single 3-g oral dose of fosfomycin tromethamine, high urinary and prostatic tissue concentrations are achieved above the minimal inhibitory concentrations of the common uropathogens within 4&#x000a0;h and persist for 48&#x000a0;h <xref rid="b0065" ref-type="bibr">[13]</xref>, <xref rid="b0070" ref-type="bibr">[14]</xref>.</p><p>The present prospective randomised study aimed at comparing the incidence of infectious complications after TRUSBx using single-dose fosfomycin (3&#x000a0;g) vs. standard FQ-based prophylaxis.</p></sec><sec id="s0010"><title>Patients and methods</title><p>Patients undergoing TRUSBx were enrolled into a prospective randomised study at the Alexandria University Department of Urology. Indications were an elevated PSA level and/or an abnormal finding on DRE. The study was approved by our Local Research and Ethics Committee.</p><p>The urine analysis and urine cultures, conducted 5&#x000a0;days before the TRUSBx, were negative for infection in all the study patients. The patients with a history of allergy or intolerance to anyone of the study drugs, UTI with positive urine culture, indwelling urinary catheters, and antibiotic use during the previous 4&#x000a0;weeks were excluded.</p><p>Patients were randomly divided into two groups: Group 1, received single-dose fosfomycin (3&#x000a0;g, orally) 1&#x02013;2&#x000a0;h before TRUSBx and Group 2 received routine empirical prophylaxis in the form of oral ciprofloxacin 500&#x000a0;mg and metronidazole 500&#x000a0;mg at least 1&#x000a0;h before TRUSBx and continued this twice daily for 3&#x000a0;days before TRUSBx. Randomisation was performed using sealed opaque envelopes; sealed envelopes were placed into a box and mixed. Allocation concealment was achieved by using an independent person &#x02018;biopsy nurse&#x02019; who blindly selected one of the sealed opaque envelopes. Thus patients were randomly allocated to Group 1 or Group 2 before the procedure. We recorded all febrile and afebrile UTIs within 4&#x000a0;weeks of TRUSBx.</p><sec id="s0015"><title>Technique of TRUSBx</title><p>Informed consent was obtained from all patients before TRUSBx, after they had been instructed by the physician regarding all possible complications. Patients were strictly advised not to take non-steroidal anti-inflammatories and anticoagulant medications for a week before the TRUSBx, to minimise the risk of bleeding and associated complications with continuation.</p><p>All TRUSBx were performed in an outpatient clinic setting using a 7-MHz probe. After prophylactic antibiotic administration, biopsies were taken with the patient in the left decubital position using an automated biopsy gun with a disposable 18-G biopsy needle. No rectal cleansing enema was used. A standardised template-based series of TRUSBx was taken through a systematic approach (a standard 12-core biopsy taken from the base, mid-gland, apex of the right and left sides of the lateral and far-lateral peripheral zone). Two transitional zone biopsies were added in case of a previous history of negative biopsies.</p><p>We prospectively recorded the following variables in all patients: age, PSA level, prostate volume, diabetic status, and prior history of TRUSBx. Urine cultures were conducted 2&#x000a0;weeks after the TRUSBx in all patients. Urine and blood cultures were obtained from patients admitted with a suspicion of a post-TRUSBx febrile UTI.</p><p>UTI, defined as the association of leucocyturia (&#x0003e;5 cells/high-power field) and significant bacteriuria (&#x0003e;105/mL) within 4&#x000a0;weeks of the procedure and the antimicrobial-resistance pattern of the strains were noted. Sepsis was defined as a fever of &#x0003e;38&#x000a0;&#x000b0;C in the presence of constitutional symptoms.</p><p>The primary endpoint was the occurrence of post-TRUSBx infectious complications as evidenced by fever (&#x0003e;38&#x000a0;&#x000b0;C) in any patient who underwent TRUSBx within the proceeding 4&#x000a0;weeks and presenting with rigours and/or any one of the following LUTS e.g. dysuria, frequency, urgency or suprapubic pain.</p></sec><sec id="s0020"><title>Statistical analysis</title><p>This study was designed to detect a 10% difference between the incidence of infectious complications after TRUSBx using single-dose fosfomycin vs. standard FQ-based prophylaxis with 80% power assuming a significant difference level of 0.05 and two-sided statistical testing. The sample size was estimated to be 400 patients (200 patients in each group). We aimed to enrol 440 patients to take into account withdrawals. Statistical analyses were performed with SPSS version 21.0 (Chicago, IL, USA) statistical software package. The two groups were compared with the independent samples <italic>t</italic>-test and chi-squared test. Statistical significance was set as a <italic>P</italic>&#x000a0;&#x0003c;&#x000a0;0.05.</p></sec></sec><sec id="s0025"><title>Results</title><p>In all, 440 patients were randomly divided into the two groups (220 patients/group) between February 2012 and June 2015. We had 28 withdrawals (18 patients in Group 1 and 10 in Group 2). Consequently, 412 patients completed the entire treatment protocol (<xref rid="f0005" ref-type="fig">Fig. 1</xref>); Group 1 (202 patients) who received single-dose fosfomycin (3&#x000a0;g, orally) and Group 2 (210) who received routine empirical prophylaxis in the form of oral ciprofloxacin 500&#x000a0;mg and metronidazole 500&#x000a0;mg.</p><p>There was no significant difference between the two groups in baseline demographics, except for there being more patients with a prior history of TRUSBx in Group 1.</p><p>Total infectious complications occurred in four (1.9%) and 18 (8.5%) patients in Groups 1 and 2, respectively, which was statistically significant (<italic>P</italic>&#x000a0;=&#x000a0;0.001). There were no cases of septic shock and no deaths. Of the four patients in Group 1 with infectious complications, three developed afebrile UTI after TRUSBx and one had febrile UTI in the form of prostatitis including bacteriuria, leucocyturia, general and urinary symptoms. Of the 18 patients in Group 2 with infectious complications, 14 (78%) developed afebrile UTI, whilst four (22%) presented with febrile UTI in the form of pyelonephritis (two) and prostatitis (two). Antibiotic regimens were adjusted according to the antimicrobial susceptibility testing results of urine cultures. All patients with febrile UTI were considered cured after 4&#x000a0;weeks of antibiotics (<xref rid="t0005" ref-type="table">Table 1</xref>).</p><sec id="s0030"><title>Culture results</title><p>Post-TRUSBx blood cultures were negative in all patients who presented with febrile UTI. Organisms identified in the urine cultures in Group 1 were <italic>E. coli</italic> (two), <italic>Streptococcus</italic> (one) and <italic>Pseudomonas</italic> (one), of which three of the four patients were FQ resistant. In Group 2, the organisms identified were <italic>E. coli</italic> (13), <italic>Klebsiella pneumoniae</italic> (four) and <italic>Staphylococcus epidermidis</italic> (one), of which 13 of the 18 patients (72%) were FQ resistant (<xref rid="t0010" ref-type="table">Table 2</xref>).</p></sec><sec id="s0035"><title>Patients with infectious complications (22/412, 5.3%)</title><p><italic>E. coli</italic> was the most common isolated pathogen in the urine cultures in all patients with infectious complications (68%). The other isolated bacterium, <italic>K. pneumoniae</italic>, was detected in four of the 22 patients (18%). Urine cultures revealed FQ-resistant strains (16 of 22; 73%), all of which were extended-spectrum &#x003b2;-lactamase (ESBL)-producing <italic>E. coli</italic> and <italic>K. pneumoniae</italic>.</p><p>There were no side-effects due to the antibiotic regimen in either group. Antimicrobial susceptibility of the urine isolates of patients with afebrile and febrile UTIs are shown in <xref rid="t0010" ref-type="table">Table 2</xref>. Minor haematuria and bleeding per rectum were recorded in 46 patients (25 in Group 1 vs. 21 in Group 2) after TRUSBx, with no case of significant bleeding requiring hospitalisation or blood transfusion.</p></sec></sec><sec id="s0040"><title>Discussion</title><p>The increasing prevalence of multidrug-resistant (MDR) infections is a major worldwide concern. This is especially true for Gram-negative organisms, for which increasing resistance to currently available antibiotics is particularly apparent. FQ-resistant Gram-negative bacilli are currently reported with increasing frequency throughout the world and are currently responsible for increased infectious complications after TRUSBx <xref rid="b0075" ref-type="bibr">[15]</xref>.</p><p>One of the MDR mechanisms that have emerged is the ESBLs, primarily in <italic>E. coli</italic>, <italic>Klebsiella</italic> and <italic>Proteus mirabilis</italic>. Bacteria that produce these enzymes are able to inactivate extended-spectrum cephalosporins and monobactams; furthermore, the plasmids that transmit ESBLs also carry resistance determinants for trimethoprim/sulphamethoxazole, FQs, and aminoglycosides <xref rid="b0080" ref-type="bibr">[16]</xref>. Carbapenems were considered the antimicrobials of choice for these organisms, although this was complicated by the development of carbapenemase-producing <italic>K. pneumoniae</italic> the following decade <xref rid="b0085" ref-type="bibr">[17]</xref>.</p><p>Recently, there has been renewed interest in the somewhat historical antibiotics such as fosfomycin, in view of the limited choices of antibiotics available to treat infections associated with these pathogens. Fosfomycin formulations are relatively safe and non-allergenic <xref rid="b0090" ref-type="bibr">[18]</xref>. Fosfomycin is a natural phosphonic antibiotic that acts by blocking bacterial cell wall synthesis by inhibiting phosphoenolpyruvate transferase, an enzyme involved in the initial stage of peptidoglycan synthesis <xref rid="b0090" ref-type="bibr">[18]</xref>. This inhibition is bactericidal and occurs at an earlier step than the action of &#x003b2;-lactams or glycopeptides <xref rid="b0095" ref-type="bibr">[19]</xref>. In addition, fosfomycin decreases bacterial adhesion to uroepithelial cells, and has the ability to penetrate biofilms, which may contribute to its effectiveness in the treatment of UTIs. Fosfomycin formulations do not appear to exhibit cross-resistance with other antimicrobials, perhaps because of their unique mechanism of action and lack of structural relationship to other known antibiotics, allowing it to retain activity against MDR organisms <xref rid="b0100" ref-type="bibr">[20]</xref>, <xref rid="b0105" ref-type="bibr">[21]</xref>. Fosfomycin has a broad-spectrum activity against a wide variety of aerobic and anaerobic bacteria including Gram-positive and Gram-negative bacteria and has shown excellent results in the treatment of uncomplicated UTIs.</p><p>Fosfomycin, administered as a single oral dose, has been shown to be well tolerated and have a favourable safety profile in multiple studies. The primary adverse effects of the oral formulations are mild gastrointestinal distress, fatigue, and headache. A potential concern that may be associated with fosfomycin treatment is the emergence of resistance <xref rid="b0110" ref-type="bibr">[22]</xref>. Despite its clinical use, emergence of uropathogens resistant to fosfomycin has been reported in few studies; therefore, fosfomycin could also be recommended as a prophylactic before endourological procedures <xref rid="b0115" ref-type="bibr">[23]</xref>.</p><p>A prospective study by Gardiner et al. <xref rid="b0120" ref-type="bibr">[24]</xref> studied the penetration of fosfomycin into benign prostatic tissue in a large cohort of otherwise healthy men undergoing TURP. They detected that fosfomycin achieved reasonable intraprostatic concentrations in the inflamed prostate after a single 3-g oral dose and pointed out that fosfomycin may be a potential alternative for pre-TRUSBx antibiotic prophylaxis and possibly for the treatment of multidrug-resistant Gram-negative bacterial prostatitis.</p><p>Clinical data about the prophylactic use fosfomycin before TRUSBx is relatively limited. A recent prospective randomised study by Volkan et al. <xref rid="b0125" ref-type="bibr">[25]</xref> reported that single-dose fosfomycin is as effective and safe as single-dose 500&#x000a0;mg oral ciprofloxacin for antibiotic prophylaxis before TRUSBx. Fosfomycin was also found to be as safe and effective as ciprofloxacin and levofloxacin in two studies: in the retrospective study by Ong&#x000fc;n et al. <xref rid="b0130" ref-type="bibr">[26]</xref>, who compared single-dose fosfomycin with single-dose levofloxacin and 500&#x000a0;mg oral ciprofloxacin twice daily administered for 5&#x000a0;days starting 1&#x000a0;day before the procedure; and Lista et al. <xref rid="b0135" ref-type="bibr">[27]</xref>, who compared double doses of fosfomycin with 500&#x000a0;mg oral ciprofloxacin twice daily administered for 5&#x000a0;days starting 1&#x000a0;day before the procedure in a prospective randomised study.</p><p>The findings of the present study are similar to other published reports on the efficacy of fosfomycin for TRUSBx antimicrobial prophylaxis, moreover, our results revealed that fosfomycin was associated with a significant reduction in infectious complications when compared with standard FQ therapy in patients undergoing TRUSBx (<italic>P</italic>&#x000a0;=&#x000a0;0.001). In all patients with infectious complications (22 patients), <italic>E. coli</italic> was the most common isolated pathogen from urine cultures (15/22, 68%), with FQ-resistant strains reaching 73% (16/22), all of which were ESBL-producing <italic>E. coli</italic> and <italic>K. pneumoniae</italic>. This might explain the superiority of fosfomycin over FQ in preventing post-TRUSBx infectious complications.</p><p>We have recently reconsidered the routine empirical administration of FQs before TRUSBx, especially after we observed an increase in post-TRUSBx infectious complications, particularly in patients who had used FQs in the 6&#x000a0;months before the TRUSBx. We chose fosfomycin as an alternative prophylactic antibiotic to the standard FQ regimen because of its convenience as an oral single-dose therapy with expected enhanced compliance, lower cost, and possibly fewer adverse events, in comparison with longer antibiotic regimens. In addition, a high concentration of fosfomycin is achieved in urine and prostatic tissue after a single dose. Fosfomycin has a broad spectrum of activity and is well tolerated. Yet, considerations regarding the achievement of microbiological eradication, as well as the emergence of microbiological relapse or re-infection, may arise. Further study of this promising agent, on a larger scale with a longer follow-up, seems warranted in the current climate of increasing resistance to current standard prophylactic antibiotic regimens.</p><p>We acknowledge several limitations of the present study. First, there might be a recall bias, relying on patient recall for past histories of TRUSBx, it is possible that some patients might have forgotten these past events, therefore, underestimating the total number of patients with a past history of TRUSBx. Second, a prior history of TRUSBx was significantly higher in Group 1, which could make the sample not comparable regarding repeated infection and prostatitis. Finally, lack of culture standardisation in microbiological laboratories may represent a limiting factor.</p></sec><sec id="s0045"><title>Conclusion</title><p>Single-dose fosfomycin before TRUSBx significantly reduces infectious complications when compared with standard FQ-based therapy. Fosfomycin is an effective agent for antimicrobial prophylaxis in patients undergoing TRUSBx, particularly in populations where FQ resistance is common.</p></sec><sec id="s0050"><title>Conflict of interest</title><p>None to declare.</p></sec><sec id="s0055"><title>Source of funding</title><p>None.</p></sec></body><back><ref-list><title>References</title><ref id="b0005"><label>1</label><element-citation publication-type="journal" id="h0005"><person-group person-group-type="author"><name><surname>Tal</surname><given-names>R.</given-names></name><name><surname>Livne</surname><given-names>P.</given-names></name><name><surname>Lask</surname><given-names>D.</given-names></name><name><surname>Baniel</surname><given-names>J.</given-names></name></person-group><article-title>Empirical management of urinary tract infections complicating transrectal ultrasound guided prostate biopsy</article-title><source>J Urol</source><volume>169</volume><year>2003</year><fpage>1762</fpage><lpage>1765</lpage><pub-id pub-id-type="pmid">12686828</pub-id></element-citation></ref><ref id="b0010"><label>2</label><element-citation publication-type="journal" id="h0010"><person-group person-group-type="author"><name><surname>Kapoor</surname><given-names>D.A.</given-names></name><name><surname>Klimberg</surname><given-names>I.W.</given-names></name><name><surname>Malek</surname><given-names>G.H.</given-names></name><name><surname>Wegenke</surname><given-names>J.D.</given-names></name><name><surname>Cox</surname><given-names>C.E.</given-names></name><name><surname>Patterson</surname><given-names>A.L.</given-names></name></person-group><article-title>Single-dose oral ciprofloxacin versus placebo for prophylaxis during transrectal prostate biopsy</article-title><source>Urology</source><volume>52</volume><year>1998</year><fpage>552</fpage><lpage>558</lpage><pub-id pub-id-type="pmid">9763070</pub-id></element-citation></ref><ref id="b0015"><label>3</label><element-citation publication-type="journal" id="h0015"><person-group person-group-type="author"><name><surname>Sieber</surname><given-names>P.</given-names></name><name><surname>Rommel</surname><given-names>F.</given-names></name><name><surname>Agusta</surname><given-names>V.</given-names></name><name><surname>Breslin</surname><given-names>J.</given-names></name><name><surname>Huffnagle</surname><given-names>H.</given-names></name><name><surname>Harpster</surname><given-names>L.E.</given-names></name></person-group><article-title>Antibiotic prophylaxis in ultrasound guided transrectal prostate biopsy</article-title><source>J Urol</source><volume>157</volume><year>1997</year><fpage>2199</fpage><lpage>2200</lpage><pub-id pub-id-type="pmid">9146614</pub-id></element-citation></ref><ref id="b0020"><label>4</label><element-citation publication-type="journal" id="h0020"><person-group person-group-type="author"><name><surname>Puig</surname><given-names>J.</given-names></name><name><surname>Darnell</surname><given-names>A.</given-names></name><name><surname>Berm&#x000fa;dez</surname><given-names>P.</given-names></name><name><surname>Malet</surname><given-names>A.</given-names></name><name><surname>Serrate</surname><given-names>G.</given-names></name><name><surname>Bar&#x000e9;</surname><given-names>M.</given-names></name></person-group><article-title>Transrectal ultrasound-guided prostate biopsy: is antibiotic prophylaxis necessary?</article-title><source>Eur Radiol</source><volume>16</volume><year>2006</year><fpage>939</fpage><lpage>943</lpage><pub-id pub-id-type="pmid">16391904</pub-id></element-citation></ref><ref id="b0025"><label>5</label><element-citation publication-type="journal" id="h0025"><person-group person-group-type="author"><name><surname>Aron</surname><given-names>M.</given-names></name><name><surname>Rajeev</surname><given-names>T.P.</given-names></name><name><surname>Gupta</surname><given-names>N.P.</given-names></name></person-group><article-title>Antibiotic prophylaxis for transrectal needle biopsy of the prostate: a randomized controlled study</article-title><source>BJU Int</source><volume>85</volume><year>2000</year><fpage>682</fpage><lpage>685</lpage><pub-id pub-id-type="pmid">10759665</pub-id></element-citation></ref><ref id="b0030"><label>6</label><element-citation publication-type="journal" id="h0030"><person-group person-group-type="author"><name><surname>Feliciano</surname><given-names>J.</given-names></name><name><surname>Teper</surname><given-names>E.</given-names></name><name><surname>Ferrandino</surname><given-names>M.</given-names></name><name><surname>Macchia</surname><given-names>R.J.</given-names></name><name><surname>Blank</surname><given-names>W.</given-names></name><name><surname>Grunberger</surname><given-names>I.</given-names></name></person-group><article-title>The incidence of fluoroquinolone resistant infections after prostate biopsy are fluoroquinolones still effective prophylaxis?</article-title><source>J Urol</source><volume>179</volume><year>2008</year><fpage>952</fpage><lpage>955</lpage><pub-id pub-id-type="pmid">18207185</pub-id></element-citation></ref><ref id="b0035"><label>7</label><element-citation publication-type="journal" id="h0035"><person-group person-group-type="author"><name><surname>Horcajada</surname><given-names>J.P.</given-names></name><name><surname>Busto</surname><given-names>M.</given-names></name><name><surname>Grau</surname><given-names>S.</given-names></name><name><surname>Sorl&#x000ed;</surname><given-names>L.</given-names></name><name><surname>Terradas</surname><given-names>R.</given-names></name><name><surname>Salvad&#x000f3;</surname><given-names>M.</given-names></name></person-group><article-title>High prevalence of extended spectrum beta lactamase-producing enterobacteriaceae in bacteremia after transrectal ultrasound-guided prostate biopsy: a need for changing preventive protocol</article-title><source>Urology</source><volume>74</volume><year>2009</year><fpage>1195</fpage><lpage>1199</lpage><pub-id pub-id-type="pmid">19811805</pub-id></element-citation></ref><ref id="b0040"><label>8</label><element-citation publication-type="journal" id="h0040"><person-group person-group-type="author"><name><surname>Young</surname><given-names>J.L.</given-names></name><name><surname>Liss</surname><given-names>M.A.</given-names></name><name><surname>Szabo</surname><given-names>R.J.</given-names></name></person-group><article-title>Sepsis due to fluoroquinolone-resistant <italic>Escherichia Coli</italic> after transrectal ultrasound-guided prostate needle biopsy</article-title><source>Urology</source><volume>74</volume><year>2009</year><fpage>332</fpage><lpage>338</lpage><pub-id pub-id-type="pmid">19464041</pub-id></element-citation></ref><ref id="b0045"><label>9</label><element-citation publication-type="journal" id="h0045"><person-group person-group-type="author"><name><surname>Cormio</surname><given-names>L.</given-names></name><name><surname>Berardi</surname><given-names>B.</given-names></name><name><surname>Callea</surname><given-names>A.</given-names></name><name><surname>Fiorentino</surname><given-names>N.</given-names></name><name><surname>Sblendorio</surname><given-names>D.</given-names></name><name><surname>Zizzi</surname><given-names>V.</given-names></name></person-group><article-title>Antimicrobial prophylaxis for transrectal prostatic biopsy: a prospective study of ciprofloxacin vs. piperacillin/tazobactam</article-title><source>BJU Int</source><volume>90</volume><year>2002</year><fpage>700</fpage><lpage>702</lpage><pub-id pub-id-type="pmid">12410751</pub-id></element-citation></ref><ref id="b0050"><label>10</label><element-citation publication-type="journal" id="h0050"><person-group person-group-type="author"><name><surname>Cam</surname><given-names>K.</given-names></name><name><surname>Kayikci</surname><given-names>A.</given-names></name><name><surname>Akman</surname><given-names>Y.</given-names></name><name><surname>Erol</surname><given-names>A.</given-names></name></person-group><article-title>Prospective assessment of the efficacy of single dose versus traditional 3-day antimicrobial prophylaxis in 12-core transrectal prostate biopsy</article-title><source>Int J Urol</source><volume>15</volume><year>2008</year><fpage>997</fpage><lpage>1001</lpage><pub-id pub-id-type="pmid">18721198</pub-id></element-citation></ref><ref id="b0055"><label>11</label><element-citation publication-type="journal" id="h0055"><person-group person-group-type="author"><name><surname>Ho</surname><given-names>H.S.</given-names></name><name><surname>Ng</surname><given-names>L.G.</given-names></name><name><surname>Tan</surname><given-names>Y.H.</given-names></name><name><surname>Yeo</surname><given-names>M.</given-names></name><name><surname>Cheng</surname><given-names>C.W.</given-names></name></person-group><article-title>Intramuscular gentamicin improves the efficacy of ciprofloxacin as an antibiotic prophylaxis for transrectal prostate biopsy</article-title><source>Ann Acad Med Singapore</source><volume>38</volume><year>2009</year><fpage>212</fpage><lpage>216</lpage><pub-id pub-id-type="pmid">19347074</pub-id></element-citation></ref><ref id="b0060"><label>12</label><element-citation publication-type="journal" id="h0060"><person-group person-group-type="author"><name><surname>Batura</surname><given-names>D.</given-names></name><name><surname>Rao</surname><given-names>G.G.</given-names></name><name><surname>Nielson</surname><given-names>P.B.</given-names></name><name><surname>Charlett</surname><given-names>A.</given-names></name></person-group><article-title>Adding amikacin to fluoroquinolone-based antimicrobial prophylaxis reduces prostate biopsy infection rates</article-title><source>BJU Int</source><volume>107</volume><year>2010</year><fpage>760</fpage><lpage>764</lpage><pub-id pub-id-type="pmid">21029317</pub-id></element-citation></ref><ref id="b0065"><label>13</label><element-citation publication-type="journal" id="h0065"><person-group person-group-type="author"><name><surname>Patel</surname><given-names>S.S.</given-names></name><name><surname>Balfour</surname><given-names>J.A.</given-names></name><name><surname>Bryson</surname><given-names>H.M.</given-names></name></person-group><article-title>Fosfomycin tromethamine: a review of its antibacterial activity, pharmacokinetic properties and therapeutic efficacy as a single-dose oral treatment for acute uncomplicated lower urinary tract infections</article-title><source>Drugs</source><volume>53</volume><year>1997</year><fpage>637</fpage><lpage>656</lpage><pub-id pub-id-type="pmid">9098664</pub-id></element-citation></ref><ref id="b0070"><label>14</label><element-citation publication-type="journal" id="h0070"><person-group person-group-type="author"><name><surname>Roussos</surname><given-names>N.</given-names></name><name><surname>Karageorgopoulos</surname><given-names>D.E.</given-names></name><name><surname>Samonis</surname><given-names>G.</given-names></name><name><surname>Falagas</surname><given-names>M.E.</given-names></name></person-group><article-title>Clinical significance of the pharmacokinetic and pharmacodynamic characteristics of fosfomycin for the treatment of patients with systemic infections</article-title><source>Int J Antimicrob Agents</source><volume>34</volume><year>2009</year><fpage>506</fpage><lpage>515</lpage><pub-id pub-id-type="pmid">19828298</pub-id></element-citation></ref><ref id="b0075"><label>15</label><element-citation publication-type="journal" id="h0075"><person-group person-group-type="author"><name><surname>Savard</surname><given-names>P.</given-names></name><name><surname>Perl</surname><given-names>T.M.</given-names></name></person-group><article-title>A call for action: managing the emergence of multidrug-resistant enterobacteriaceae in the acute care settings</article-title><source>Curr Opin Infect Dis</source><volume>25</volume><year>2012</year><fpage>371</fpage><lpage>377</lpage><pub-id pub-id-type="pmid">22766646</pub-id></element-citation></ref><ref id="b0080"><label>16</label><element-citation publication-type="journal" id="h0080"><person-group person-group-type="author"><name><surname>Nicasio</surname><given-names>A.</given-names></name><name><surname>Kuti</surname><given-names>J.</given-names></name><name><surname>Nicolau</surname><given-names>D.</given-names></name></person-group><article-title>The current state of multidrug resistant gram-negative bacilli in North America: insights from the Society of Infectious Diseases Pharmacists</article-title><source>Pharmacotherapy</source><volume>28</volume><year>2008</year><fpage>235</fpage><lpage>249</lpage><pub-id pub-id-type="pmid">18225969</pub-id></element-citation></ref><ref id="b0085"><label>17</label><element-citation publication-type="journal" id="h0085"><person-group person-group-type="author"><name><surname>Yigit</surname><given-names>H.</given-names></name><name><surname>Queenan</surname><given-names>A.M.</given-names></name><name><surname>Anderson</surname><given-names>G.J.</given-names></name><name><surname>Domenech-Sanchez</surname><given-names>A.</given-names></name><name><surname>Biddle</surname><given-names>J.W.</given-names></name><name><surname>Steward</surname><given-names>C.D.</given-names></name></person-group><article-title>Novel carbapenem hydrolyzing beta-lactamase, KPC-1, from a carbapenem-resistant strain of Klebsiella pneumoniae</article-title><source>Antimicrob Agents Chemother</source><volume>45</volume><year>2001</year><fpage>1151</fpage><lpage>1161</lpage><pub-id pub-id-type="pmid">11257029</pub-id></element-citation></ref><ref id="b0090"><label>18</label><element-citation publication-type="journal" id="h0090"><person-group person-group-type="author"><name><surname>Raz</surname><given-names>R.</given-names></name></person-group><article-title>Fosfomycin: an old&#x02013;new antibiotic</article-title><source>Clin Microbiol Infect</source><volume>18</volume><year>2012</year><fpage>4</fpage><lpage>7</lpage><pub-id pub-id-type="pmid">21914036</pub-id></element-citation></ref><ref id="b0095"><label>19</label><element-citation publication-type="journal" id="h0095"><person-group person-group-type="author"><name><surname>Popovic</surname><given-names>M.</given-names></name><name><surname>Steinort</surname><given-names>D.</given-names></name><name><surname>Pillai</surname><given-names>S.</given-names></name><name><surname>Joukhadar</surname><given-names>C.</given-names></name></person-group><article-title>Fosfomycin: an old, new friend?</article-title><source>Eur J Clin Microbiol Infect Dis</source><volume>29</volume><year>2010</year><fpage>127</fpage><lpage>142</lpage><pub-id pub-id-type="pmid">19915879</pub-id></element-citation></ref><ref id="b0100"><label>20</label><element-citation publication-type="journal" id="h0100"><person-group person-group-type="author"><name><surname>Pogue</surname><given-names>J.M.</given-names></name><name><surname>Marchaim</surname><given-names>D.</given-names></name><name><surname>Kaye</surname><given-names>D.</given-names></name><name><surname>Kaye</surname><given-names>K.S.</given-names></name></person-group><article-title>Revisiting &#x0201c;older&#x0201d; antimicrobials in the era of multidrug resistance</article-title><source>Pharmacotherapy</source><volume>31</volume><year>2011</year><fpage>912</fpage><lpage>921</lpage><pub-id pub-id-type="pmid">21923592</pub-id></element-citation></ref><ref id="b0105"><label>21</label><element-citation publication-type="journal" id="h0105"><person-group person-group-type="author"><name><surname>Garau</surname><given-names>J.</given-names></name></person-group><article-title>Other antimicrobials of interest in the era of extended-spectrum beta-lactamases: fosfomycin, nitrofurantoin and tigecycline</article-title><source>Clin Microbiol Infect</source><volume>14</volume><issue>Suppl. 1</issue><year>2008</year><fpage>198</fpage><lpage>202</lpage><pub-id pub-id-type="pmid">18154548</pub-id></element-citation></ref><ref id="b0110"><label>22</label><element-citation publication-type="journal" id="h0110"><person-group person-group-type="author"><name><surname>Gupta</surname><given-names>K.</given-names></name><name><surname>Hooton</surname><given-names>T.M.</given-names></name><name><surname>Stamm</surname><given-names>W.E.</given-names></name></person-group><article-title>Isolation of fluoroquinolone-resistant rectal <italic>Escherichia coli</italic> after treatment of acute uncomplicated cystitis</article-title><source>J Antimicrob Chemother</source><volume>56</volume><year>2005</year><fpage>243</fpage><lpage>246</lpage><pub-id pub-id-type="pmid">15911548</pub-id></element-citation></ref><ref id="b0115"><label>23</label><element-citation publication-type="journal" id="h0115"><person-group person-group-type="author"><name><surname>Falagas</surname><given-names>M.E.</given-names></name><name><surname>Giannopoulou</surname><given-names>K.P.</given-names></name><name><surname>Kokolakis</surname><given-names>G.N.</given-names></name><name><surname>Rafailidis</surname><given-names>P.I.</given-names></name></person-group><article-title>Fosfomycin: use beyond urinary tract and gastrointestinal infections</article-title><source>Clin Infect Dis</source><volume>46</volume><year>2008</year><fpage>1069</fpage><lpage>1077</lpage><pub-id pub-id-type="pmid">18444827</pub-id></element-citation></ref><ref id="b0120"><label>24</label><element-citation publication-type="journal" id="h0120"><person-group person-group-type="author"><name><surname>Gardiner</surname><given-names>B.J.</given-names></name><name><surname>Mahony</surname><given-names>A.A.</given-names></name><name><surname>Ellis</surname><given-names>A.G.</given-names></name><name><surname>Lawrentschuk</surname><given-names>N.</given-names></name><name><surname>Bolton</surname><given-names>D.M.</given-names></name><name><surname>Zeglinski</surname><given-names>P.T.</given-names></name></person-group><article-title>Is fosfomycin a potential treatment alternative for multidrug-resistant Gram-negative prostatitis?</article-title><source>Clin Infect Dis</source><volume>58</volume><year>2014</year><fpage>e101</fpage><lpage>e105</lpage><pub-id pub-id-type="pmid">24170195</pub-id></element-citation></ref><ref id="b0125"><label>25</label><element-citation publication-type="journal" id="h0125"><person-group person-group-type="author"><name><surname>Sen</surname><given-names>V.</given-names></name><name><surname>Aydogdu</surname><given-names>O.</given-names></name><name><surname>Bozkurt</surname><given-names>I.H.</given-names></name><name><surname>Yonguc</surname><given-names>T.</given-names></name><name><surname>Sen</surname><given-names>P.</given-names></name><name><surname>Polat</surname><given-names>S.</given-names></name></person-group><article-title>The use of prophylactic single-dose fosfomycin in patients who undergo transrectal ultrasound-guided prostate biopsy: a prospective, randomized, and controlled clinical study</article-title><source>Can J Urol</source><volume>9</volume><year>2015</year><fpage>E863</fpage><lpage>E867</lpage></element-citation></ref><ref id="b0130"><label>26</label><element-citation publication-type="journal" id="h0130"><person-group person-group-type="author"><name><surname>Ong&#x000fc;n</surname><given-names>S.</given-names></name><name><surname>Aslan</surname><given-names>G.</given-names></name><name><surname>Avkan-Oguz</surname><given-names>V.</given-names></name></person-group><article-title>The effectiveness of single-dose fosfomycin as antimicrobial prophylaxis for patients undergoing transrectal ultrasound-guided biopsy of the prostate</article-title><source>Urol Int</source><volume>89</volume><year>2012</year><fpage>439</fpage><lpage>444</lpage><pub-id pub-id-type="pmid">23006631</pub-id></element-citation></ref><ref id="b0135"><label>27</label><element-citation publication-type="journal" id="h0135"><person-group person-group-type="author"><name><surname>Lista</surname><given-names>F.</given-names></name><name><surname>Redondo</surname><given-names>C.</given-names></name><name><surname>Meil&#x000e1;n</surname><given-names>E.</given-names></name><name><surname>Garc&#x000ed;a-Tello</surname><given-names>A.</given-names></name><name><surname>Ram&#x000f3;n de Fata</surname><given-names>F.</given-names></name><name><surname>Angulo</surname><given-names>J.C.</given-names></name></person-group><article-title>Efficacy and safety of fosfomycin-trometamol in the prophylaxis for transrectal prostate biopsy. Prospective randomized comparison with ciprofloxacin</article-title><source>Actas Urol Esp</source><volume>38</volume><year>2014</year><fpage>391</fpage><lpage>396</lpage><pub-id pub-id-type="pmid">24775812</pub-id></element-citation></ref></ref-list><fn-group><fn id="d32e228"><p id="np015">Peer review under responsibility of Arab Association of Urology.</p></fn></fn-group></back><floats-group><fig id="f0005"><label>Figure 1</label><caption><p>Study flow diagram.</p></caption><graphic xlink:href="gr1"/></fig><table-wrap id="t0005" position="float"><label>Table 1</label><caption><p>Patient characteristics and infectious complications of the two groups.</p></caption><table frame="hsides" rules="groups"><thead><tr><th>Variable</th><th>Group 1<break/>Fosfomycin</th><th>Group 2<break/>Standard FQ</th><th><italic>P</italic></th></tr></thead><tbody><tr><td>Number of patients</td><td>202</td><td>210</td><td/></tr><tr><td colspan="4">Mean (SD):</td></tr><tr><td>&#x000a0;Age, years</td><td>68.8 (4.2)</td><td>62.5 (2.8)</td><td align="char">0.62</td></tr><tr><td>&#x000a0;Prostate volume, mL</td><td>67.3 (31.2)</td><td>59.8 (28.5)</td><td align="char">0.08</td></tr><tr><td>Mean (SE) PSA level, ng/mL</td><td>23.9 (5.8)</td><td>17.8 (3.2)</td><td align="char">0.06</td></tr><tr><td>Prior TRUSBx, <italic>n</italic></td><td>13</td><td>5</td><td>0.03<xref rid="tblfn1" ref-type="table-fn">&#x0204e;</xref></td></tr><tr><td colspan="4"><italic>N</italic> (%):</td></tr><tr><td>&#x000a0;Afebrile UTI</td><td>3 (75)</td><td>14 (78)</td><td align="char">0.001</td></tr><tr><td>&#x000a0;Febrile UTI</td><td>1 (25)</td><td>4 (22)</td><td/></tr></tbody></table><table-wrap-foot><fn id="tblfn1"><label>&#x0204e;</label><p id="np005">Statistically significant.</p></fn></table-wrap-foot></table-wrap><table-wrap id="t0010" position="float"><label>Table 2</label><caption><p>Antimicrobial susceptibility of the urine isolates of patients with afebrile and febrile UTIs.</p></caption><table frame="hsides" rules="groups"><thead><tr><th>Variable</th><th>Group 1<break/>Fosfomycin</th><th>Group 2<break/>Standard FQ</th><th><italic>P</italic></th></tr></thead><tbody><tr><td>Number of patients</td><td>4</td><td>18</td><td>0.001<xref rid="tblfn2" ref-type="table-fn">&#x0204e;</xref></td></tr><tr><td>Afebrile UTI, <italic>n</italic></td><td>3</td><td>14</td><td align="char"/></tr><tr><td>&#x000a0;FQ-sensitive</td><td>1</td><td>5</td></tr><tr><td>&#x000a0;FQ-resistant</td><td>2</td><td>9</td></tr><tr><td>Febrile UTI, <italic>n</italic></td><td>1</td><td>4</td><td align="char"/></tr><tr><td>&#x000a0;FQ-sensitive</td><td>&#x02013;</td><td>&#x02013;</td></tr><tr><td>&#x000a0;FQ-resistant</td><td>1</td><td>4</td></tr></tbody></table><table-wrap-foot><fn id="tblfn2"><label>&#x0204e;</label><p id="np010">Statistically significant.</p></fn></table-wrap-foot></table-wrap></floats-group></article>